Shire PLC (NASDAQ:SHPG) Given a $213.00 Price Target by Royal Bank Of Canada Analysts
A number of other research analysts have also commented on SHPG. Goldman Sachs Group, Inc. (The) reiterated a conviction-buy rating on shares of Shire PLC in a report on Friday, April 14th. Jefferies Group LLC set a $239.00 target price on Shire PLC and gave the company a buy rating in a research note on Thursday, April 20th. HSBC Holdings plc lowered Shire PLC from a hold rating to a reduce rating in a research note on Friday, May 19th. Sanford C. Bernstein lowered Shire PLC from an outperform rating to a market perform rating and cut their target price for the company from $209.22 to $161.09 in a research note on Thursday, May 25th. Finally, Cowen and Company restated an outperform rating and issued a $325.00 target price on shares of Shire PLC in a research note on Wednesday, May 31st. Two equities research analysts have rated the stock with a sell rating, six have assigned a hold rating and sixteen have assigned a buy rating to the stock. The stock presently has an average rating of Buy and an average price target of $223.18.
Shire PLC (SHPG) traded down 3.51% during mid-day trading on Friday, hitting $155.91. 2,263,388 shares of the stock were exchanged. The firm has a market cap of $46.44 billion, a P/E ratio of 159.91 and a beta of 1.60. Shire PLC has a one year low of $155.06 and a one year high of $209.22.
Shire PLC (NASDAQ:SHPG) last issued its quarterly earnings results on Thursday, August 3rd. The biopharmaceutical company reported $3.73 EPS for the quarter, topping analysts’ consensus estimates of $3.53 by $0.20. Shire PLC had a return on equity of 14.32% and a net margin of 4.70%. The company had revenue of $3.75 billion during the quarter, compared to analyst estimates of $3.73 billion. During the same period in the previous year, the company earned $3.38 earnings per share. The company’s quarterly revenue was up 54.2% compared to the same quarter last year. Equities analysts anticipate that Shire PLC will post $14.88 earnings per share for the current fiscal year.
COPYRIGHT VIOLATION WARNING: This story was originally posted by Daily Political and is owned by of Daily Political. If you are accessing this story on another site, it was stolen and reposted in violation of international copyright & trademark legislation. The correct version of this story can be viewed at https://www.dailypolitical.com/2017/08/05/shire-plc-nasdaqshpg-given-a-213-00-price-target-by-royal-bank-of-canada-analysts.html.
Several institutional investors have recently modified their holdings of SHPG. Federated Investors Inc. PA raised its position in shares of Shire PLC by 38.8% in the second quarter. Federated Investors Inc. PA now owns 9,153 shares of the biopharmaceutical company’s stock valued at $1,513,000 after buying an additional 2,560 shares during the period. iAB Financial Bank raised its position in shares of Shire PLC by 8.9% in the second quarter. iAB Financial Bank now owns 6,340 shares of the biopharmaceutical company’s stock valued at $1,048,000 after buying an additional 520 shares during the period. Marshall Wace LLP raised its position in shares of Shire PLC by 6.5% in the second quarter. Marshall Wace LLP now owns 538,704 shares of the biopharmaceutical company’s stock valued at $88,886,000 after buying an additional 32,813 shares during the period. Addenda Capital Inc. raised its position in shares of Shire PLC by 3.2% in the second quarter. Addenda Capital Inc. now owns 5,089 shares of the biopharmaceutical company’s stock valued at $731,000 after buying an additional 160 shares during the period. Finally, Gamco Investors INC. ET AL raised its position in shares of Shire PLC by 15.2% in the second quarter. Gamco Investors INC. ET AL now owns 6,904 shares of the biopharmaceutical company’s stock valued at $1,141,000 after buying an additional 912 shares during the period. 21.05% of the stock is currently owned by institutional investors and hedge funds.
Shire PLC Company Profile
Shire plc is a biotech company focused on serving people with rare diseases and other specialized conditions. The Company’s segment is engaged in research, development, licensing, manufacturing, marketing, distribution and sale of specialist medicines. It focuses its development resources on projects in various therapeutic areas (TAs), including Neuroscience, Ophthalmology, Hematology, Oncology, Immunology, Gastrointestinal (GI)/Metabolic/Endocrinology Diseases.
Receive News & Ratings for Shire PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Shire PLC and related companies with MarketBeat.com's FREE daily email newsletter.